Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study
The purpose of the study is to look at the levels of three HIV medications darunavir, ritonavir and atazanavir in the blood after the drug intake has been stopped in order to understand how long these drugs persist in blood for. The study will specifically look at these three drugs blood levels after taking them for 10 days everyday.
The main objective is to provide information on the potential safety (in terms of preventing virological failure and the development of resistance)of delaying drug doses occasionally by providing information on the decline in drug concentration after dosing has stopped.
|HIV HIV Infections||Drug: darunavir/ritonavir then atazanavir/ritonavir||Phase 1|
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Pharmacokinetics of Darunavir/Ritonavir Once Daily and Atazanavir/Ritonavir Once Daily Over 72 Hours Following Drug Intake Cessation|
- Pharmacokinetics [ Time Frame: 30 days (excluding screening and follow-up) ]To assess the pharmacokinetics of darunavir/ritonavir once daily and atazanavir/ritonavir once daily over 72 hours following drug intake cessation
- Inter-Subject Variability [ Time Frame: 30 days ]To assess the inter subject variability in darunavir and atazanavir plasma concentrations over 72 hours following drug intake cessation.
- Safety and Tolerability [ Time Frame: 30 day (excluding screening and follow up) ]To assess the safety and tolerability of darunavir/ritonavir and atazanavir/ritonavir over 10 days of administration
- Pharmacogenetics [ Time Frame: 30 day (excluding screening and follow up) ]To investigate the association between genetic polymorphisms in drug disposition genes and drug exposure
|Study Start Date:||April 2010|
|Study Completion Date:||June 2010|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
All Subjects will receive the same intervention
Drug: darunavir/ritonavir then atazanavir/ritonavir
Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days
Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT01073761
|St Stephen's Centre|
|London, United Kingdom, SW10 9TH|
|Principal Investigator:||Marta Boffito, Dr||St Stephen's AIDS Trust|